[HTML][HTML] Wnt/beta-catenin pathway: modulating anticancer immune response
Wnt/β-catenin signaling, a highly conserved pathway through evolution, regulates key
cellular functions including proliferation, differentiation, migration, genetic stability …
cellular functions including proliferation, differentiation, migration, genetic stability …
[HTML][HTML] Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and …
Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The
therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of …
therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of …
[HTML][HTML] Repurposing metformin for cancer treatment: current clinical studies
YK Chae, A Arya, MK Malecek, DS Shin, B Carneiro… - Oncotarget, 2016 - ncbi.nlm.nih.gov
In recent years, several studies have presented evidence suggesting a potential role for
metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer …
metformin in anti-cancer therapy. Preclinical studies have demonstrated several anticancer …
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
[HTML][HTML] Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
ES Kim, V Velcheti, T Mekhail, C Yun, SM Shagan… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in
predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess …
predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess …
[HTML][HTML] Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
YK Chae, K Ranganath, PS Hammerman, C Vaklavas… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase
signaling pathway that has a fundamental role in many biologic processes including …
signaling pathway that has a fundamental role in many biologic processes including …
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors
SP Patel, M Othus, YK Chae, FJ Giles, DE Hansel… - Clinical Cancer …, 2020 - AACR
Purpose: Immune checkpoint blockade has improved outcomes across tumor types; little is
known about the efficacy of these agents in rare tumors. We report the results of the …
known about the efficacy of these agents in rare tumors. We report the results of the …
[HTML][HTML] Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)
YK Chae, S Chang, T Ko, J Anker, S Agte, W Iams… - Scientific reports, 2018 - nature.com
Epithelial-mesenchymal transition (EMT) is able to drive metastasis during progression of
multiple cancer types, including non-small cell lung cancer (NSCLC). As resistance to …
multiple cancer types, including non-small cell lung cancer (NSCLC). As resistance to …
Role of human aquaporin 5 in colorectal carcinogenesis
SK Kang, YK Chae, J Woo, MS Kim, JC Park… - The American journal of …, 2008 - Elsevier
While overexpression of several aquaporins (AQPs) has been reported in different types of
human cancer, the role of AQPs in carcinogenesis has not been clearly defined. Here, by …
human cancer, the role of AQPs in carcinogenesis has not been clearly defined. Here, by …
Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins
YK Chae, ME Valsecchi, J Kim, AL Bianchi… - Cancer …, 2011 - Taylor & Francis
Background: Epidemiologic and biochemical evidence suggest a role of statins and
angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as …
angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as …